Milacemide
From Wikipedia, the free encyclopedia
![]() |
|
Names | |
---|---|
IUPAC name
2-(Pentylamino)acetamide[1]
|
|
Identifiers | |
76990-56-2 ![]() |
|
3D model (Jmol) | Interactive image Interactive image |
ChEMBL | ChEMBL75838 ![]() |
ChemSpider | 48376 ![]() |
MeSH | milacemide |
PubChem | 53569 |
UNII | 0HXT24RECU ![]() |
|
|
|
|
Properties | |
C7H16N2O | |
Molar mass | 144.22 g·mol−1 |
log P | 0.754 |
Related compounds | |
Related compounds
|
Tricine |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
Infobox references | |
Milacemide (INN)[2] is an MAO-B inhibitor and glycine prodrug.[3] It has been studied for its effects on human memory and as a potential treatment for the symptoms of Alzheimer's disease.[4] Early clinical trials did not show positive results however,[3] and the drug is now abandoned.
References[edit]
- ^ "milacemide - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 8 August 2005. Identifiers and Related Records. Retrieved 9 January 2012.
- ^ "International Nonproprietary Names for Pharmaceutical Substances. Supplement to WHO Chronicle, 1983, Vol. 37, No. 6 (December). Recommended International Nonproprietary Names (Rec. INN): List 23" (PDF). World Health Organization. p. 6. Retrieved 8 January 2016.
- ^ a b Dysken, MW; Mendels, J; LeWitt, P; Reisberg, B; Pomara, N; Wood, J; Skare, S; Fakouhi, JD; Herting, RL (May 1992). "Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.". Journal of the American Geriatrics Society. 40 (5): 503–6. PMID 1634705.
- ^ Harris, Carol Turkington ; foreword by Joseph R. (2002). The encyclopedia of the brain and brain disorders (2nd ed.). New York, NY: Facts on File. ISBN 0-8160-4774-X.
![]() |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |